News

August 28, 2020August 28, 2020

Nepexto, Biosimilar of Enbrel, Now Available in Germany

News

Nepexto, a biosimilar of Enbrel (etanercept), is now available in Germany for patients with juvenile idiopathic arthritis (JIA) and other inflammatory conditions, according to Lupin Limited and Mylan, the treatment’s developers. ... Read more

August 21, 2020August 21, 2020

Humira Shows Long-term Efficacy and Safety in Polyarticular JIA, Phase 3 Trial Reports

News

Long-term treatment with Humira (adalimumab) — reaching through six years — was well-tolerated and effective in children with polyarticular juvenile idiopathic arthritis (JIA), a Phase 3 trial with an extension ... Read more

August 7, 2020August 7, 2020

JIA Type and Medication Use Affect Longevity of Joint Implants, Study Reports

News

How long implants last in people with juvenile idiopathic arthritis (JIA) who had joint replacement surgery depends on disease type, year of surgery, number of complications, and medication use before ... Read more

July 24, 2020July 24, 2020

sJIA Patients May Benefit More From Biologics Than Non-systemic, Review Finds

News

Biological therapies or biologics may be more beneficial for young people with systemic juvenile idiopathic arthritis (sJIA) than for those with non-systemic disease, according to a review study. The ... Read more

July 17, 2020July 17, 2020

Fundraisers and Fun Mark July, Juvenile Arthritis Awareness Month

News

With a goal of dispelling the common notion that only seniors get arthritis, Juvenile Arthritis Awareness Month efforts are underway. The juvenile arthritis community is observing the annual July event, organized ... Read more

July 10, 2020July 10, 2020

Hulio, Biosimilar of Humira, Wins FDA Approval for JIA, But Not Available Until 2023

News

The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), for the treatment of juvenile idiopathic arthritis (JIA) in individuals ages 4 and older. However, the biosimilar ... Read more

June 19, 2020June 19, 2020

MEFV Gene Mutation May Be Risk Factor for sJIA, Study Suggests

News

A specific mutation in the MEFV gene, which has been linked to inflammation, may be a risk factor for developing systemic juvenile idiopathic arthritis (sJIA), a study in China ... Read more

June 12, 2020June 12, 2020

Enbrel Biosimilar Nepexto Approved in Europe for JIA, Other Inflammatory Disorders

News

The European Commission has approved Nepexto, a biosimilar of Enbrel (etanercept), for the treatment of juvenile idiopathic arthritis and other inflammatory disorders. Nepexto is expected to be available to patients in the European ... Read more

June 5, 2020June 5, 2020

Teens in Netherlands Can Disregard Disease in Planning for Future, Survey Finds

News

Teenagers with juvenile idiopathic arthritis (JIA) in the Netherlands show a desire for “normalcy” and willingness not to consider their disease in career plans, voicing in a survey hopes ... Read more

May 29, 2020May 29, 2020

Nearly One-fifth of Infections Opportunistic in JIA Children on Immunosuppressants, Study Reports

News

Close to one-fifth of infections in children with juvenile idiopathic arthritis (JIA) on immunosuppressants are caused by opportunistic pathogens — such as microorganisms that take advantage of weakened immune ... Read more

Pin It on Pinterest